Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer

Trial Profile

A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Trastuzumab (Primary) ; Anthracyclines; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors EirGenix
  • Most Recent Events

    • 02 Jan 2019 Planned End Date changed from 3 Sep 2021 to 31 Jul 2021.
    • 02 Jan 2019 Planned primary completion date changed from 26 Aug 2020 to 5 Aug 2020.
    • 02 Jan 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top